Core Insights - Changchun High-tech announced a collaboration with Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mite (HDM) allergens [1] - The agreement includes an initial payment of €32.7 million, with additional milestone payments totaling €40 million for regulatory approval and up to €105 million based on sales performance in China [1] - The global allergy immunotherapy market is projected to reach $3.2 billion by 2030, with a compound annual growth rate (CAGR) of 9.5%, highlighting significant growth potential in this sector [1] Company Summary - JinSai Pharmaceutical, a subsidiary of Changchun High-tech, will lead the collaboration and has secured exclusive rights to three products developed by ALK for the Chinese market [1] - The partnership aims to address the unmet clinical needs in China, where the number of patients receiving desensitization therapy is currently below 1 million, despite having the largest population of house dust mite allergy sufferers globally [1] Industry Summary - The allergy immunotherapy market in China is underdeveloped and lacks innovative products, presenting a substantial opportunity for growth [1] - The collaboration is expected to enhance the availability of effective treatments for a significant patient population suffering from dust mite allergies in China [1]

Group 1 - The core point of the article is that Changchun High-tech (000661) has entered into a collaboration with Danish company ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products in China [1] - Changchun Jin Sai Pharmaceutical, a subsidiary of Changchun High-tech, will have exclusive rights to three ALK-developed products in mainland China, including subcutaneous allergen preparations, skin prick test kits, and sublingual tablets [1] - The collaboration agreement grants Changchun Jin Sai Pharmaceutical exclusive rights until December 31, 2039, and involves an upfront payment of €32.7 million for the commercialization rights of the three products [1]

Core Viewpoint - Changchun High-tech (000661) announced a collaboration with Denmark's ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products for house dust mites (HDM) in China, gaining exclusive rights for three products in the mainland market [1] Group 1: Partnership Details - The partnership involves Changchun High-tech's subsidiary, Jinsai Pharmaceutical, which will pay an upfront fee of €32.7 million for the collaboration [1] - Jinsai Pharmaceutical will also make a milestone payment of €40 million based on the clinical trial regulatory approval progress for the sublingual tablet (ACARIZAX) for adults, adolescents, and children in China [1] - Future payments of up to €105 million may be made depending on the sales performance of the products in the Chinese market [1]